As shown in supplementary figure S4 , the pooled data analysis showed a trend towards a reduction in the development of pulmonary infection in patients receiving HFPV compared to those receiving conventional iMV (risk ratio 0.74 (95% CI: 0.54–1.00); p=0.05; I 2 39%).
1
—
—